ATE286511T1 - Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren - Google Patents

Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren

Info

Publication number
ATE286511T1
ATE286511T1 AT00301103T AT00301103T ATE286511T1 AT E286511 T1 ATE286511 T1 AT E286511T1 AT 00301103 T AT00301103 T AT 00301103T AT 00301103 T AT00301103 T AT 00301103T AT E286511 T1 ATE286511 T1 AT E286511T1
Authority
AT
Austria
Prior art keywords
vertebrate
immune response
fusion protein
fusion proteins
peptide
Prior art date
Application number
AT00301103T
Other languages
English (en)
Inventor
Manuel Campos
Serge Rene Martinod
Becky Ann Durtschi
Terecita Dolores Yule
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE286511T1 publication Critical patent/ATE286511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00301103T 1999-02-17 2000-02-14 Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren ATE286511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12045499P 1999-02-17 1999-02-17

Publications (1)

Publication Number Publication Date
ATE286511T1 true ATE286511T1 (de) 2005-01-15

Family

ID=22390397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00301103T ATE286511T1 (de) 1999-02-17 2000-02-14 Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren

Country Status (10)

Country Link
US (2) US6911206B1 (de)
EP (1) EP1035133B1 (de)
JP (1) JP2000236887A (de)
AT (1) ATE286511T1 (de)
BR (1) BR0000489A (de)
CA (1) CA2297441A1 (de)
DE (1) DE60017211T2 (de)
DK (1) DK1035133T3 (de)
ES (1) ES2233284T3 (de)
PT (1) PT1035133E (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233284T3 (es) * 1999-02-17 2005-06-16 Pfizer Products Inc. Proteinas de fusion que comprenden portadores que pueden inducir una bdoble respuesta inmune.
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
WO2004105791A2 (en) * 2003-06-02 2004-12-09 The Talwar Research Foundation Recombinant anti-lhrh vaccines
EP1742659B1 (de) * 2004-04-05 2013-03-13 Pah Usa 15 Llc Mikrofluidisierte öl-in-wasser-emulsionen und vakzinezusammensetzungen
US8524247B2 (en) 2008-09-17 2013-09-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus-based recombinant immunocontraceptive compositions and methods of use
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
KR101145911B1 (ko) 2008-12-22 2012-05-15 한국화학연구원 대장균의 외막단백질 ＯｍｐＷ를 이용한 목적단백질의 표면발현 방법
AU2014287005C1 (en) * 2013-07-12 2021-06-03 The Children's Hospital Of Philadelphia AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies
CN113517025B (zh) * 2020-04-10 2022-03-18 西咸新区予果微码生物科技有限公司 一种病原体在线监测***及方法
CN112979789B (zh) * 2021-04-14 2021-07-27 北京市农林科学院 用于检测牛传染性鼻气管炎病毒的中和抗体的阻断elisa试剂盒及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
GB2140810B (en) 1983-05-24 1987-07-08 Celltech Ltd Polypeptide and protein products, and process for their production
GB8314362D0 (en) 1983-05-24 1983-06-29 Celltech Ltd Polypeptide and protein products
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
EP0175261B1 (de) 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4975420A (en) 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
JPH01171489A (ja) 1987-12-26 1989-07-06 Chemo Sero Therapeut Res Inst 狂犬病ウイルス糖蛋白質をコードする遺伝子断片およびこれを用いた狂犬病ウイルス糖蛋白質の製法
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
EP0396653A1 (de) * 1988-08-30 1990-11-14 Applied Research Systems ARS Holding N.V. Rekombinante schmelz-proteine zur modifizierung der hormonabscheidung
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
EP0446313B1 (de) * 1989-08-25 1996-07-31 Biotechnology Australia Pty. Ltd. Fusionsproteine bestehend aus TraTp und mindestens einem LHRH-Analog
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
GB9007416D0 (en) 1990-04-02 1990-05-30 Wellcome Found Expression of heterologous protein in yeast
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
DE69121877T2 (de) 1991-02-01 1997-04-03 Bmra Corp Bv Verfahren zur Messung der Aktivität angiotensinkonvertierenden Enzyms in biologischen Proben
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
GB9201013D0 (en) 1992-01-17 1992-03-11 Animal Health Inst Vaccines
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5441736A (en) 1992-11-05 1995-08-15 University Of Saskatchewan Actinobacillus pleuropneumoniae outer membrane lipoprotein A and uses thereof
WO1994024296A2 (en) 1993-04-19 1994-10-27 University Of Saskatchewan Recombinant bovine herpesvirus type 1 vaccines
US5545523A (en) 1993-05-28 1996-08-13 Cornell Research Foundation, Inc. Methods of detecting bovine herpesvirus 1 (BHV-1) in semen by nucleic acid amplification
JP2577304B2 (ja) 1993-07-23 1997-01-29 大日本製薬株式会社 ヒト インターロイキン１活性を有するポリペプチド
US5599663A (en) 1993-08-27 1997-02-04 Brighan & Women's Hospital Angiotensin IV and analogs as regulators of fibrinolysis
DE69429450T2 (de) 1993-09-24 2002-07-25 University Of Southern California, Los Angeles Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
US5786179A (en) 1994-02-28 1998-07-28 Agritech Technologies Ltd. Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same
ATE235959T1 (de) 1994-04-15 2003-04-15 Univ Temple Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
IL112581A0 (en) 1995-02-08 1995-05-26 Moreh Ronen Pop rivet
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
AUPO776897A0 (en) 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
ES2233284T3 (es) * 1999-02-17 2005-06-16 Pfizer Products Inc. Proteinas de fusion que comprenden portadores que pueden inducir una bdoble respuesta inmune.

Also Published As

Publication number Publication date
EP1035133A2 (de) 2000-09-13
DK1035133T3 (da) 2005-05-02
ES2233284T3 (es) 2005-06-16
DE60017211T2 (de) 2005-06-02
BR0000489A (pt) 2001-05-02
CA2297441A1 (en) 2000-08-17
EP1035133B1 (de) 2005-01-05
JP2000236887A (ja) 2000-09-05
DE60017211D1 (de) 2005-02-10
US6911206B1 (en) 2005-06-28
US20050095258A1 (en) 2005-05-05
EP1035133A3 (de) 2002-09-25
PT1035133E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
BR0014282A (pt) Vacinas
WO1999010375A3 (en) Vaccine against hpv
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
DE69735854D1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
EA200201280A1 (ru) Стрептококковые антигены
WO2000039299A3 (en) Streptococcus antigens
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
PT759935E (pt) L1 de virus de papiloma recombinante
GB9626483D0 (en) Helicobacter proteins and vaccines
CA2047792A1 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
WO1999042588A3 (en) Group b streptococcus antigens
DE60017211D1 (de) Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
CA2132742A1 (en) Synthetic Peptides and Vaccines Against Parvovirus
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
HU9200583D0 (en) Method for producing el peptides of rubeola
WO2001034184A3 (en) Methods and compositions for protection against bovine herpesvirus 1
ATE530563T1 (de) Rekombinante proteine einer pakistanischen hepatitis e variante und ihre verwendung in diagnoseverfahren und impfungen
ITRM910385A0 (it) Vaccini utilizzanti eritrociti come veicoli di antigeni.
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2001055181A3 (en) Recombinant multivalent malarial vaccines against plasmodium vivax
CA2141670A1 (en) Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
ATE123302T1 (de) Rhoptry-membran-antigen von -i(plasmodium falciparum).
ES1027961U (es) Soporte publicitario para carritos.
MX9700215A (es) Proteinas y vacunas de helicobacter.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1035133

Country of ref document: EP

REN Ceased due to non-payment of the annual fee